-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Acetazolamide + Dronabinol) in Obstructive Sleep Apnea
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Acetazolamide + Dronabinol) in Obstructive Sleep Apnea report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Acetazolamide + Dronabinol) in Obstructive Sleep Apnea Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Annamycin in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Annamycin in Relapsed Acute Myeloid Leukemia Drug Details: L-Annamycin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma Drug Details: ADCT-601(BGB-601)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis Drug Details: IHL-675A, a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Lung Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Lung Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Lung Disease Drug Details: IHL-675A, a...
-
Product Insights
NewRestless Legs Syndrome – Drugs In Development, 2024
Empower your strategies with our Restless Legs Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling, and cramping in the calf or leg muscles. A predisposing factor is age. Treatment includes muscle relaxants, sleep medications, and narcotic medications. The...
-
Product Insights
NewChemotherapy Induced Nausea and Vomiting – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Nausea and Vomiting – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced nausea and vomiting (CINV) is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Other symptoms include a rapid heart rate, sweating, dizziness, and increased saliva. Risk factors include age, drug, dose, and the schedule and route of the drug's administration. The Chemotherapy Induced Nausea and Vomiting drugs in development market research report provide comprehensive information...
-
Product Insights
NewObstructive Sleep Apnea – Drugs In Development, 2024
Empower your strategies with our Obstructive Sleep Apnea – Drugs In Development, 2024 report and make more profitable business decisions. Obstructive sleep apnea (OSA) is defined by episodes of either complete collapse or partial collapse of the airway during sleep, accompanied by a reduction in oxygen saturation or awakening from sleep. This disruption leads to fragmented and nonrestorative sleep. The implications of OSA extend to various aspects of health, including cardiovascular well-being, mental health, overall quality of life, and safety while...
-
Product Insights
NewPostherpetic Neuralgia – Drugs In Development, 2024
Empower your strategies with our Postherpetic Neuralgia – Drugs In Development, 2024 report and make more profitable business decisions. Postherpetic neuralgia (PHN) emerges as the predominant long-term consequence of varicella-zoster virus (VZV) reactivation, commonly known as herpes zoster or shingles. VZV, responsible for childhood varicella (chickenpox), historically affected the majority of American adults before widespread vaccination. While future generations may experience lower rates of herpes zoster and PHN, the latter remains clinically significant. PHN diagnosis heavily relies on history and physical...